Showing results (91-100 of 102) with videos related to

Sort By:
Pageof 11
Neuro-Oncology|January 24, 2025
Phase II Trial of Brain MRI Surveillance in Stage IV Breast CancerKamran A Ahmed, Youngchul Kim, Avan J Armaghani, et al.
Neuro-Oncology Advances|March 26, 2025
Phase 1 trial of hypofractionated stereotactic re-irradiation in combination with nivolumab, ipilimumab, and bevacizumab for recurrent high-grade gliomasSolmaz Sahebjam, Raju R Raval, Peter A Forsyth, et al.
Neuro-Oncology|May 27, 2026
Breaking Barriers in Leptomeningeal Disease: A SNO-ASCO Consensus Review on Clinical Trial Design and Basic Science IntegrationYolanda Piña, Maxine Umeh Garcia, Adrienne Boire, et al.
The New England Journal of Medicine|August 23, 2018
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the BrainHussein A Tawbi, Peter A Forsyth, Alain Algazi, et al.
Biorxiv : the Preprint Server for Biology|January 8, 2024
Branched-chain keto acids promote an immune-suppressive and neurodegenerative microenvironment in leptomeningeal diseaseMariam Lotfy Khaled, Yuan Ren, Ronak Kundalia, et al.
Journal for Immunotherapy of Cancer|April 28, 2025
Nivolumab and stereotactic radiosurgery for patients with breast cancer brain metastases: long-term results and biomarker analysis from a non-randomized, open-label, phase Ib studyKamran A Ahmed, Younchul Kim, Sungjune Kim, et al.
Neuro-Oncology|November 11, 2020
Hypofractionated stereotactic re-irradiation with pembrolizumab and bevacizumab in patients with recurrent high-grade gliomas: results from a phase I studySolmaz Sahebjam, Peter A Forsyth, Nam D Tran, et al.
Advances in Radiation Oncology|December 22, 2021
Nivolumab and Stereotactic Radiosurgery for Patients With Breast Cancer Brain Metastases: A Nonrandomized, Open-Label Phase 1b StudyKamran A Ahmed, Youngchul Kim, John A Arrington, et al.
Neuro-Oncology|April 21, 2021
Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)Hussein A Tawbi, Peter A Forsyth, F Stephen Hodi, et al.
The Lancet. Oncology|November 14, 2021
Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 studyHussein A Tawbi, Peter A Forsyth, F Stephen Hodi, et al.
Pageof 11